Severe periorbital edema secondary to STI571 (Gleevec).
STI571 (imatinib mesylate; Gleevec) is a selective inhibitor of the bcr-abl, c-kit, and platelet-derived growth factor receptor tyrosine kinases. Mild periorbital edema has been noted as a common side effect in Phase I and II trials of this drug for the treatment of patients with chronic myelogenous leukemia and gastrointestinal stromal tumors. The authors report the case of male patient age 63 years who developed severe periorbital edema after treatment with STI571 for chronic myelogenous leukemia. His edema was severe enough to cause visual obstruction due to lower eyelid festoons that ultimately required surgical debulking. Histopathologic analysis of specimens of the excised upper and lower eyelid tissue revealed dermal dendrocytes that expressed the platelet-derived growth factor receptor and c-kit tyrosine kinases, suggesting a possible role for dermal dendrocytes in the development of this toxic effect.
Esmaeli
Bita
B
Ophthalmology Section, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. besmaeli@mdanderson.org
Prieto
Victor G
VG
Butler
Charles E
CE
Kim
Stella K
SK
Ahmadi
M Amir
MA
Kantarjian
Hagop M
HM
Talpaz
Moshe
M
D001549:Benzamides; D004487:Edema / Q000139:chemically induced*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009915:Orbit / Q000033:anatomy & histology; D009916:Orbital Diseases / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000009:adverse effects*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases